Sector Expert: Charles Duncan

Piper Jaffray & Co.

Image: Charles Duncan

Dr. Charles Duncan is a managing director and senior research analyst at Piper Jaffray & Co. focusing on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 18 years of sellside experience and has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • Cara Therapeutics Inc.
  • Catalyst Pharmaceutical Partners Inc.
  • CTI BioPharma
  • Inovio Pharmaceuticals Inc.
  • Vascular Pharmaceuticals
  • vTv Therapeutics Inc.


Recent Interviews

Piper Jaffray's Charles Duncan Addresses Pot Shots (6/26/14)

Early-stage biotech is a risky investment, but some bets are safer than others. Inovio Pharmaceuticals Inc. is doing high-stakes experimental work in both preventive and therapeutic medicine, addressing HIV, cancers and pre-cancers. The company's lead clinical program is in Phase 2 and a data readout is imminent, which has made the stock both volatile and an easy target for critics. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Managing Director Charles Duncan of Piper Jaffray & Co. addresses some of the criticisms that overhang the stock.

Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers (4/24/14)

Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and Duncan believes now is the time to identify, through careful diligence, companies that can advance in a more temperate market. In this interview with The Life Sciences Report, Duncan discusses five biotech and specialty pharma innovators poised to produce therapies enabled by versatile and scalable technology platforms that target multiple disease indications.

Recent Quotes

"INO has received external validation on SynCon's flexibility and broad potential in infectious disease."

— Charles Duncan, Piper Jaffray & Co. (1/27/16)
more >

"We reiterate our Overweight rating on INO."

— Charles Duncan, Piper Jaffray & Co. (9/21/15)
more >

"The MedImmune deal further enhances our confidence in INO's DNA immunotherapy."

— Charles Duncan, Piper Jaffray & Co. (8/10/15)
more >

"We are increasing our target price for INO and we reiterate our Overweight rating."

— Charles Duncan, Piper Jaffray & Co. (5/11/15)
more >

"INO's INO-1800 for HBV will be evaluated with and without INO-9112."

— Charles Duncan, Piper Jaffray & Co. (4/21/15)
more >

"INO's SynCon is a leading immunooncology DNA-based therapeutic vaccine platform."

— Charles Duncan, Piper Jaffray & Co. (4/9/15)
more >

"DARPA's grant provides INO with funding to advance its pipeline."

— Charles Duncan, Piper Jaffray & Co. (4/8/15)
more >

"INO's clinical programs are advancing well, in line with expectations."

— Charles Duncan, Piper Jaffray & Co. (3/16/15)
more >

more comments

"Updated data from INO's Phase 2 VGX-3100 trial for CD are positive."

— Charles Duncan, Piper Jaffray & Co. (3/5/15)
more >

"Topline data from THLD's Phase 3 are expected still in Q1/16."

— Charles Duncan, Piper Jaffray & Co. (12/4/14)
more >

"Data from the Phase 1/3 GBM trial for THLD's TH-302 look positive."

— Charles Duncan, Piper Jaffray & Co. (11/17/14)
more >

"INO should initiate multiple clinical trials before year-end."

— Charles Duncan, Piper Jaffray & Co. (11/10/14)
more >

"THLD's Q3/14E cash was $68M; this is sufficient at least into 2016."

— Charles Duncan, Piper Jaffray & Co. (11/4/14)
more >

"INO is moving its Ebola DNA vaccine into Phase 1 trials with GeneOne."

— Charles Duncan, Piper Jaffray & Co. (9/25/14)
more >

"We reiterate our Overweight rating on THLD."

— Charles Duncan, Piper Jaffray & Co. (9/22/14)
more >

"INO's $109M in cash at Q2/14E should fund operations through 2017."

— Charles Duncan, Piper Jaffray & Co. (8/11/14)
more >

"THLD's Phase 3 TH-302 safety/efficacy data are expected in September."

— Charles Duncan, Piper Jaffray & Co. (8/1/14)
more >

"INO's first controlled test of its platform met the primary endpoint."

— Charles Duncan, Piper Jaffray & Co. (7/23/14)
more >

"BDSI's second Phase 3 buprenorphine study met its primary endpoint."

— Charles Duncan, Piper Jaffray & Co. (7/7/14)
more >

"BDSI's Phase 3 data for BBCP are expected in the next few weeks."

— Charles Duncan, Piper Jaffray & Co. (6/27/14)
more >

"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study."

The Life Sciences Report Interview with Charles Duncan (6/26/14)
more >

"INO's near-term catalyst is its ongoing Phase 2 in cervical dysplasia."

— Charles Duncan, Piper Jaffray & Co. (6/24/14)
more >

"Results from INO's Phase 2, VGX-3100 in CD study is a key data point."

— Charles Duncan, Piper Jaffray & Co. (6/17/14)
more >

"The FDA approved BDSI's Bunavail for treating opioid dependence."

— Charles Duncan, Piper Jaffray & Co. (6/8/14)
more >

"THLD's TH-302 programs in multiple myeloma and glioblastoma multiforme are becoming increasingly visible."

— Charles Duncan, Piper Jaffray & Co. (6/3/14)
more >

"The dismissed suit is a clear positive for BDSI."

— Charles Duncan, Piper Jaffray & Co. (5/22/14)
more >

"CPRX will likely be first to market with orphan designation in LEMS."

— Charles Duncan, Piper Jaffray & Co. (5/22/14)
more >

"BDSI has a strong cash position and numerous upcoming catalysts."

— Charles Duncan, Piper Jaffray & Co. (5/12/14)
more >

"INO's Phase 2a data would provide key validation of the platform."

— Charles Duncan, Piper Jaffray & Co. (5/12/14)
more >

"We model THLD as fully funded through at least 2015."

— Charles Duncan, Piper Jaffray & Co. (5/2/14)
more >

"THLD's soft-tissue sarcoma study should read out at the end of 2015; that could be a very exciting time."

The Life Sciences Report Interview with Charles Duncan (4/24/14)
more >

"The Phase 2 trial for VGX-3100 could be a major clinical validation of the power of INO's broadly applicable platform."

The Life Sciences Report interview with Charles Duncan (4/24/14)
more >

"By the end of 2014, you're going to have some pretty good news flow out of BDSI."

— The Life Sciences Report interview with Charles Duncan (4/24/14)
more >

"BDSI's robust presence at ASAM should raise awareness of Bunavail."

— Charles Duncan, Piper Jaffray & Co. (4/7/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.